Oppenheimer initiated coverage on shares of Compugen (NASDAQ:CGEN) in a research report released on Thursday morning, TipRanks reports. The firm issued a buy rating and a $19.00 price objective on the biotechnology company’s stock.
CGEN has been the topic of a number of other research reports. BidaskClub lowered shares of Compugen from a hold rating to a sell rating in a research report on Tuesday, July 28th. SunTrust Banks raised their price objective on Compugen from $16.00 to $22.00 and gave the company a buy rating in a report on Tuesday, April 28th. Roth Capital initiated coverage on Compugen in a report on Wednesday, April 22nd. They issued a buy rating and a $28.00 target price for the company. JMP Securities began coverage on Compugen in a research report on Tuesday, May 26th. They issued an outperform rating and a $18.00 target price for the company. Finally, ValuEngine cut Compugen from a buy rating to a hold rating in a report on Thursday, July 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. Compugen presently has a consensus rating of Buy and an average price target of $18.75.
Shares of CGEN opened at $14.41 on Thursday. Compugen has a 52-week low of $2.96 and a 52-week high of $17.85. The firm has a market cap of $985.93 million, a price-to-earnings ratio of -37.92 and a beta of 2.84. The business’s fifty day moving average is $15.10 and its 200-day moving average is $11.53.
Hedge funds have recently made changes to their positions in the stock. Steward Partners Investment Advisory LLC raised its holdings in Compugen by 700.0% during the 1st quarter. Steward Partners Investment Advisory LLC now owns 4,000 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 3,500 shares during the last quarter. Citigroup Inc. raised its stake in Compugen by 688.7% during the fourth quarter. Citigroup Inc. now owns 5,521 shares of the biotechnology company’s stock worth $33,000 after buying an additional 4,821 shares during the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in Compugen in the first quarter valued at $80,000. Philadelphia Trust Co. bought a new stake in Compugen during the first quarter valued at $109,000. Finally, Cornerstone Investment Partners LLC grew its holdings in Compugen by 4.9% during the 1st quarter. Cornerstone Investment Partners LLC now owns 18,360 shares of the biotechnology company’s stock worth $133,000 after acquiring an additional 860 shares during the period. Institutional investors and hedge funds own 46.56% of the company’s stock.
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.
Featured Story: S&P/ASX 200 Index
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.